tbuckley/cabot-search huggingface dataset:
A randomized, controlled clinical trial of a geriatric consultation team. Compliance with recommendations
Authors: C. M. Allen
Journal: JAMA (1986)

As part of a prospective, randomized, controlled study of the effectiveness of a geriatric consultation team, we examined compliance by the house staff with recommendations made by the team. Recommendations were formulated for 185 patients, aged 75 years or older, who were randomized into intervention (n = 92) and control (n=93) groups. In the control group, only 27.1% of the actions that would have been recommended by the team were implemented independently by the house staff. Problems commonly neglected included polypharmacy, sensory impairment, confusion, and depression. In the intervention group, overall compliance was 71.7%. Highest compliance occurred for recommendations addressing instability and falls (95.0%) and discharge planning (94.3%). We conclude that a geriatric consultation team contributes substantial additional input into the care of older patients. Furthermore, relatively high compliance can be achieved with recommendations made by a geriatric consultation team, thereby overcoming the first barrier to the establishment of such a service. (<i>JAMA</i>1986;255:2617-2621)
The ureter in renal transplantation.
Journal: BMJ (1966)

Puerperal schizophrenia or affective disorder is thus mainly distinguished from the corresponding non-puerperal states by the acute onset, evident external and internal stress, the social situation, the marital status of the patients, and by their age-the schizophrenic patients being rather older and the patients with affective states younger at age of onset :han is usual in non-puerperal patients.These factors are by and large associated with favourable outcome, and, since ..nese women are usually under medical surveillance, early dentification and treatment also improve the outlook.Early
Wheezes
Authors: N Meslier, G Charbonneau, JL Racineux
Journal: European Respiratory Journal (1995)

Wheezes are continuous adventitious lung sounds. The American Thoracic Society Committee on pulmonary nomenclature define wheezes as high-pitched continuous sounds with a dominant frequency of 400 Hz or more. Rhonchi are characterized as low-pitched continuous sounds with a dominant frequency of about 200 Hz or less. The large variability in the predominant frequency of wheezes is one of the difficulties encountered with automated analysis and quantification of wheezes. The large variations observed in automated wheeze characterization emphasize the need for standardization of breath sound analysis. This standardization would help determine diagnostic criteria for wheeze identification. The mechanism of wheeze production was first compared to a toy trumpet whose sound is produced by a vibrating reed. The pitch of the wheeze is dependent on the mass and elasticity of the airway walls and on the flow velocity. More recently, a model of wheeze production based on the mathematical analysis of the stability of airflow through a collapsible tube has been proposed. According to this model, wheezes are produced by the fluttering of the airways walls and fluid together, induced by a critical airflow velocity. Many circumstances are suitable for the production of continuous adventitious lung sounds. Thus, wheezes can be heard in several diseases, not only asthma. Wheezes are usual clinical signs in patients with obstructive airway diseases and particularly during acute episodes of asthma. A relationship between the degree of bronchial obstruction and the presence and characteristics of wheezes has been demonstrated in several studies. The best result is observed when the degree of bronchial obstruction is compared to the proportion of the respiratory cycle occupied by wheeze (tw/ttot). However, the relationship is too scattered to predict forced expiratory volume in one second (FEV1) from wheeze duration. There is no relationship between the intensity or the pitch of wheezes and the pulmonary function. The presence or quantification of wheezes have also been evaluated for the assessment of bronchial hyperresponsiveness. Wheeze detection cannot fully replace spirometry during bronchial provocation testing but may add some interesting information. Continuous monitoring of wheezes might be a useful tool for evaluation of nocturnal asthma and its treatment.
Anaphylaxis to a component of isoetharine (sodium bisulfite)
Authors: F. J. Twarog
Journal: JAMA (1982)

ADVERSE reactions to preservatives used in foods and medications are being recognized with increasing frequency. We have recently seen an asthmatic patient in whom wheezing and anaphylactoid symptoms developed after the administration of isoetharine hydrochloride and metoclopramide hydrochloride on separate occasions. The purpose of this report is to document that these hypersensitivity reactions resulted from sodium bisulfite, a preservative, used in the vehicles of these two drugs. <h3>Report of a Case</h3> The patient was an 18-year-old woman who had had perennial asthma since the age of 15 years. The first episode of wheezing occurred in 1974 while she was vacationing in Europe. While eating lunch, consisting of a hamburger and french fries, diffuse urticaria and wheezing developed and she required emergency therapy. She had eaten similar meals on previous occasions without difficulty. After her return to the United States, the patient experienced recurrent episodes of wheezing while eating restaurant meals.
Medical Service at the Front.
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erichsen, not Trichsen.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction:<i>Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials</i>
Authors: Su Jin Lim, Stephanie Xavier, Marcelo B Sztein, Elana J Fertig
Journal: Journal for ImmunoTherapy of Cancer (2020)
Mortality in Relation to Smoking: Ten Years' Observations of British Doctors
Authors: R. Doll, A. B. Hill
Journal: BMJ (1964)

In previous papers (Doll and Hill, 1954, 1956) we have described how at the end of October 1951 we sent a short and simple questionary to the 59,600 men and women whose names were on the current British Medical Register and who were then resident in the United Kingdom.In addition to giving name, address, and age, they were asked to say whether (a) they were, at that time, smokers of tobacco, (b) they had previously smoked but had given up, or (c) they had never smoked regularly (which we defined as having never smoked as much as one cigarette a day, or its equivalent in pipe tobacco or cigars, for as long as one year).The smokers and ex-smokers were asked the age at which they had started smoking, the amount that they smoked, and the method by which they smoked either at the time of reply or when they last gave up, and, when appropriate, the age at which they had stopped.We deliberately limited our inquiries to these very few ques- tions, partly to encourage a large number of answers and partly because we believed that these were questions that could be answered with reasonable accuracy.For such reasons we did not ask for a life-history of smoking habits nor did we, at that time, inquire into the habit of inhaling. DataTo this request we had 40,637 replies sufficiently complete to be used-34,445 from men and 6,192 from women.From a 1 in 10 random sample of the register that we subsequently drew and analysed we estimate that these figures represent answers from 69% of the men and 60% of the women alive at the time of the inquiry.' (These numbers differ slightly from those we published in 1956; from answers to our second questionary (see below) we learned that we had allotted the wrong sex to a few subjects and had included a few forms that had come from relatives who were not doctors.) Selective SampleWe may feel sure that the doctors who chose to answer were not representative of the total.The seriously ill would have been unable to respond, and thus, as we showed in our previous paper, the mortality of the group who replied would be, at least for a time, abnormally low.In fact, using the 1 in 10 sample as a basis, we calculated that the standardized
Abstract 5086: Acetyl-L-carnitine (ALCAR) inhibits angiogenesis, migration and macrophage recruitment in prostatic cancer cells
Authors: Adriana Albini, Antonino Bruno, Denisa Baci, Matteo Gallazzi, Matilde Tramacere
Journal: Cancer Research (2019)

Abstract Many efforts have been addressed on the identification of novel active compounds from natural sources, endowed with anti-proliferative, anti-oxidant, chemopreventive properties, and their ability to target the tumour microenvironment (TME). Through metabolomics approaches we previously found that in serum samples from prostate cancer (PCa) patients, three carnitine family members were significantly decreased, suggesting a potential protective role of carnitine against PCa. Acetyl-L-carnitine(ALCAR) is an aceticacid ester of carnitine with high bioavailability and is involved in the transportof fatty acids across the inner mitochondrial membrane. We have showed that ALCAR was able reduce angiogenesis in vitro, acting on the VEGF/VEGFR2 and CXCR4/CXCL12 axes. We also found that ALCAR inhibits inflammatory angiogenesis in vivo, by reducing endothelial cells and macrophage recruitment in the matrigel plugs. Here we investigated the ability of ALCAR to interfere with key functional steps of prostate carcinogenesis and identified the molecular mechanisms involved. The effects of ALCAR on PCa cells were investigated in vitro by functional assays (adhesion, migration and invasion assays), molecular and biochemical approaches (RT-PCR, FACS, Byoplex and western blot). We found that ALCAR reduces apoptosis on PCa cells (PC3, Du-145, LNcap) and inhibits crucial tumorigenic steps such as adhesion, migration and invasion. We than confirmed the results from functional assays at molecular levels, and we found that ALCAR blocks CXCR4/CXCL12 axes, a key regulator of malignant migratory/aggressive phenotype. In accordance with our published paper, we confirmed the anti-angiogenic and ant-inflammatory properties of ALCAR, that we found to lower VEGF and CXCL8 production in PCa cell lines. Furthermore, we found a significantly reduced expression of inflammatory-related chemokines/cytokines involved macrophage recruitment such as CCL2, IL-6 and TNFα in PCa cells. Our results highlight the angio/chemopreventive and anti-inflammatory properties of ALCAR and allow the identification of multiple and overlapping mechanisms of action through which ALCAR inhibits PCa progression / metastasis. Our findings provide the rational for the employment of ALCAR, as a possible supplement for approaches of chemoprevention in subjects at high risk to develop cancer. Citation Format: Adriana Albini, Antonino Bruno, Denisa Baci, Matteo Gallazzi, Matilde Tramacere. Acetyl-L-carnitine (ALCAR) inhibits angiogenesis, migration and macrophage recruitment in prostatic cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5086.
Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2010;115(22):4478-4487.
Journal: Blood (2019)
Journal of Endocrinology, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patients preferences in chemotherapy for advanced non-small-cell lung cancer in Japan
Authors: T. Hirose, N. Horichi, T. Ohmori, T. Shirai, T. Ozawa, T. Ohnishi, A. Mitsuru
Journal: Journal of Clinical Oncology (2004)

7242 Background:Although several meta-analyses have shown that chemotherapy is effective against stage IV NSCLC, increases in survival are frequently accompanied by increases in treatment toxicity. The objective of study was to determine how Japanese patients with lung cancer weigh potential survival, chemotherapy response rate, and symptom relief against the potential toxicity of different treatments in cancer chemotherapy. Methods:We used a questionnaire describing a hypothetical situation about stage IV non-small-cell lung cancer. Seventy-three patients with lung cancer who had received chemotherapy (L group) and 120 patients with other respiratory conditions (N group) as the control group were asked to rate the minimal benefit that would make two hypothetical treatments acceptable. For "chance of cure," "response but not cure," and "symptom relief" the subjects could give answers from 1% to 100% and for prolonging life could give answers from 1 to 60 months. Results:The median scores for "chance of cure" to accept intensive and less-intensive treatments were significantly lower in the L group (10% and 7%) than in the N group (50% and 30%; p<0.05). The L group was also significantly more likely to accept either intensive or less-intensive treatments for a potentially small benefit for "response," "relief of symptoms," and "prolonging life". For an increase in survival of 3 months intensive chemotherapy was acceptable to a significantly higher percentage of patients in the L group (19%) than in the N group (9%, p=0.04), but less-intensive chemotherapy was acceptable to similar percentage of patients (L group, 21%; N group, 13%; p=0.13). Factors associated with patients' choice of chemotherapy in both groups were age and the presence of dependents. Conclusions:Oncologists must consider the substantial range of attitudes to chemotherapy among patients when making decision. No significant financial relationships to disclose.
b. 1919
Authors: Robert A. Beasley
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Lectures on the Varieties of Phthisis
Authors: C. T. Williams
Journal: BMJ (1878)

thing which will show you that I perfectly understand your illness, and will enable you to believe what I say.Those dark circles under your eyes were painted by yourself' A start and an instant denial.' Do not repeat that denial, please ; I know it.You got some black stuff and rubbed it on.'More denials, but with flushed face and con- scious look.' I know it as well as if I had seen you.I will prove to you that I know it.Your paleness on the day you came here was only tooth-powder which you had rubbed on your face.'No denials now, but a startled look, tearful eyes, and helpless silence.' I do not tell you this to hurt your feelings, nor to give you pain, neither do I need to tell your friends about it; but I wish to show you that there is no mystery in your case.'The conviction was complete, and her confession was unreserved.She told me that she bad darkened her eyes with the lead from her pencil, and that she had done it because her friends thought it denoted biliousness, and so did not insist on her taking food, to which she had extreme repugnance, on account of the sickness and vomiting which eating produced.She declared her inten- tion to tell her kind friends all about it as soon as she was well, and was anxious to know if you knew all." This was the right mood, so, of course, I went on with as much quiet emphasis as possible.'You know from this that I understand your case, and now I tell you that you can perfectly control your other ailments; that the fits, the shaking of the head, and the vomiting must cease.They are not needful; they prevent you from getting well.You have the power to stop them, and I wish you to do so.'She promised to try, and, of course, she succeeded in all but the cough, which unhappily was more than nervous.Within a fortnight, I was able to report to Dr. in these words: 'No preternatural sleep, no choreic movements, no shaking of the head, no vomiting, no fits; up and out every day.'The persistence of the cough was unfor- tunately due to lung-disease.When made aware of this, her friends took her home again, and she died a few months afterwards."I trouble you with no comments ; but it is due to the memory of our most interesting patient to express my full belief that her attempts at deception did not result from" moral obliquity, but were as purely the product of disease as the abnormal sleep and the eccentric move- ments.-Yoursvery faithfully, D. YELLOWLEES." To Professor Gairdner."It seems only necessary to add to this impressive narrative a very few lines.I never saw M. T. again.
Culture Flasks for Use with Plane Surface Substrate Tissue Cultures
Authors: Earle, Wilton R., Highhouse, Frederick
Journal: JNCI Journal of the National Cancer Institute (1954)

Journal Article Culture Flasks for Use with Plane Surface Substrate Tissue Cultures Get access Wilton R. Earle, Wilton R. Earle Tissue Culture Section, Laboratory of BiologyBethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Frederick Highhouse Frederick Highhouse Instrumentation Unit, Laboratory of Biophysics, National Cancer Institute,2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 4, February 1954, Pages 841–851, https://doi.org/10.1093/jnci/14.4.841 Published: 01 February 1954 Article history Received: 10 August 1953 Published: 01 February 1954
Mechanisms of Free Radical Chemistry and Biochemistry of Benzene
Authors: Lisa R. Karam, Michael G. Simic
Journal: Environmental Health Perspectives (1989)

omicron-Tyrosine (omicron-Tyr) was used as a specific biomarker for .OH radicals generated in biosystems. Specificity of omicron-Tyr as an .OH biomarker was based on previous studies in systems exposed to ionizing radiations. Fresh muscle tissue incubated with benzene for 1 hr at 38 degrees C exhibits formation of omicron-Tyr as seen in the cases of ethanol- and carbon tetrachloride-exposed systems. Gas chromatography/mass spectrometry selective ion monitoring measurements of omicron-Tyr yields in chicken breast muscle incubated with water or benzene indicate levels of less than 0.1 ppm and 3.0 +/- 0.5 ppm of omicron-Tyr, respectively. Formation of .OH is presumed to originate via a Haber-Weiss reaction of H2O2 with Fe(II) preceded by the formation of .O2- and H2O2 from distorted mitochondria.
Drug Use
Authors: T. Donald Rucker
Journal: JAMA (1974)

It is estimated that 2.8 million prescriptions and drug orders representing an economic value of $11 billion were dispensed in the United States in 1973. There are differences in drug use according to various demographic and socioeconomic characteristics, and to physician prescribing rates and drug product rankings. Current sources of drug data are the manufacturer, prescriber, dispenser, and patient. A model information system for prescription services should be designed primarily to support professional decision-making in treating patients. There are certain specific functions for this system, and the health professions should provide leadership that will facilitate its development and operation. (<i>JAMA</i>230:888-890, 1974)